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Abundant evidences have shown that ghrelin, by its binding to GHS-R1a, plays an
important role for fundamental physiological functions. Increasing attention is given to
the GHS-R1a unusually high constitutive activity and its contribution to downstream
signaling and physiological processes. Here, we review recent lines of evidences
showing that the interaction between ligand-binding pocket TM domains and the ECL2
could be partially responsible for this high constitutive activity. Interestingly, GHSR-1a
constitutive activity activates in turn the downstream PLC, PKC, and CRE signaling
pathways and this activation is reversed by the inverse agonist [D-Arg1, D-Phe5, D-Trp7,9,
Leu11]-substance P (MSP). Noteworthy, GHSR-1a exhibits a C-terminal-dependent
constitutive internalization. Non-sense GHS-R1a mutation (Ala204Glu), first discovered in
Moroccan patients, supports the role of GHSR-1a constitutive activity in physiological
impairments. Ala204Glu-point mutation, altering exclusively the GHSR-1a constitutive
activity, was associated with familial short stature syndrome. Altogether, these findings
suggest that GHS-R1a constitutive activity could contribute to GH secretion or body
weight regulation. Consequently, future research on basic and clinical applications of
GHS-R1a inverse agonists will be challenging and potentially rewarding.
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INTRODUCTION
The secretion of growth hormone (GH) by the anterior pitu-
itary is under complex control. Small synthetic molecules termed
GH secretagogues (GHS) are synthetic, peptidyl, and non-
peptidyl molecules which possess strong and dose-dependent
GH-releasing activity in vivo in several species and in humans
(Cheng et al., 1989; Bowers et al., 1991; Cheng et al., 1991). The
cloning of the GH secretagogue receptor (GHS-R1a, now called
ghrelin receptor) in 1996 (Howard et al., 1996; Pong et al., 1996),
led to the isolation of the endogenous ligand, ghrelin in 1999
(Kojima et al., 1999).
Ghrelin is a 28 amino acid peptide that differs from all other
peptide hormones known by an octanoylation. This fatty acid
modification is essential both for the binding to and activation of
the receptor and for its pharmacokinetic properties (Kojima et al.,
2001). Ghrelin strongly stimulates GH release in humans (Bowers
et al., 1991), and it is much more potent than Growth Hormone-
Releasing Hormone (GHRH) under similar conditions. Ghrelin
potently increase food intake and weight gain, and also regulates
energy homeostasis and metabolism following central and sys-
temic administration (Castañeda et al., 2010; Stengel and Taché,
2012).
The GHS-R1a is a G protein-coupled receptor (GPCR) of
366 amino acids with the characteristic seven transmembrane-
spanning domains (7TM receptor; for review Schwartz et al.,
2006; Cruz and Smith, 2008). Signal transduction from the extra-
cellular environment via 7TM receptors in general requires a
conformational change from an inactive (R) to a active state (R∗).
Certain 7TM receptors are stabilized in an active conformation
without any ligand present. The ability to propagate the intra-
cellular signal in the absence of agonist is commonly known as
constitutive activity.
Constitutive activity is described formostly all GPCR, however
for a large part of them the level of constitutive activity is very low
(Arvanitakis et al., 1998; Smit et al., 2007).
The GHS-R1a exhibits unusual high constitutive activity
(Holst et al., 2003) as it signal with ∼50% of its maximal capac-
ity in the absence of the agonist, ghrelin. This article aims to
review the current knowledge on GHS-R1a ligand-independent
constitutive activity and its functions.
GHS-R1a AND ITS CONSTITUTIVE ACTIVITY
MOLECULAR BASIS
For several years, it has been noted that mostly all GPCRs exhibit
intrinsic constitutive activity (Arvanitakis et al., 1998; Smit et al.,
2007). In 1999, studies performed on the β2-adrenergic recep-
tor suggested that this ligand-independent activity could involve
an inward movement of the extracellular segments of the trans-
membrane domains (TMs) VI and VII toward TM III in the
ligand-binding pocket (Elling et al., 1999).
Holst and colleagues performed a structural analysis of GHS-
R1a and revealed the crucial role of an aromatic cluster formed
by three residues (Phe VI:16, Phe VII:06, and Phe VII:09) on
the inner face of the extracellular ends of GHS-R1a TMs VI
and VII. Their close spatial proximity and the formation of this
cluster allow GHS-R1a to stabilize in its active conformation in
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absence of agonist (Holst et al., 2004; Mokrosinski and Holst,
2010).
The residue in position VI:16 is central for the constitutive
activity level that can gradually be increased or decreased depend-
ing on the size and hydrophobic properties of the side chain
of the amino acid. It has also been suggested that the aromatic
residue VI:16 may work as a tethered agonist located strategically
at the interface between TM III TM VI and TM VII, blocking
these extracellular TM segments in a conformation promoting
GHS-R1a high constitutive activity (Schwartz et al., 2006).
A conserved aromatic lock crucial for GHS-R1a high basal sig-
naling level is formed by the Trp VI:13 and Phe V:13 residues
(Holst et al., 2004). The Trp VI:13 (=Trp276) is located in the
conserved motif CWxP in the middle of TM VI and is supposed
to act as a global toggle switch model allowing the inward move-
ment of this domain, and the GHS-R1a high basal activation level
(Schwartz et al., 2006; Floquet et al., 2010).
Specific residues in the vinicity of this cluster have been pro-
posed to orchestrate finely tuned microswitches critical for the
activation level in absence of ligand (Holst et al., 2004; Valentin-
Hansen et al., 2012).
In order to study the importance of this core peptide in the
GHS-R1a constitutive activity, Gozé et al. introduced the muta-
tion Trp276Ala and mutated the two surrounding amino acid
residues Val131 and Ile134. Their results revealed that the muta-
tion Trp276A1a dramatically impairs the ligand-independent
activity whereas Val131Leu and Ile134Met highly increase GHS-
R1a basal activity. According to these results, the three residues
Trp276, Val131, and Ile134 could also significantly impact on
GHS-R1a constitutive signaling (Gozé et al., 2010).
In 2006, Pantel et al. reported a mutation (Ala204Glu) in the
extracellular loop II (ECL2) of the human GHS-R1a affecting
selectively the ligand-independent activity (Pantel et al., 2006).
The ECL2 structure function analysis revealed that by restricting
this segment, and so possibly TM V/TM III, movements either by
mutation or by ligand binding, reduces the constitutive signaling
level (Mokrosinski et al., 2012), showing that the high GHS-R1a
basal signaling level depends on the flexibility in these segments.
Other studies showed that a single mutation or space generating
a substitution in the GHS-R1a sequence or in the ligand pep-
tide sequence can change the ligand properties from agonist to
inverse agonist or from inverse agonist to agonist depending on
the residue mutated (Holst et al., 2007; Els et al., 2012).
TM VI and TM VII movements into their inward-bend
promoting the ligand-independent active conformation can be
stoically blocked, using a modified substance P (MSP) inverse
agonist, [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P (often
referred in the literature as SPA, for substance P analog). The
systematic analysis of this peptide structure-function relation-
ship identified the C-terminal heptapeptide (fQwFwLL) as its
active core, the D-Phe5 residue being apparently crucial for the
inverse agonist property and the binding affinity (Holst et al.,
2006). Unlike ghrelin that only interacts with the middle part
of the ligand-binding pocket, the inverse agonist binds to an
extended-binding pocket comprising all the seven TM domains
of the receptor except for the first one. In addition, the space-
generating mutants located relatively deep in the binding pocket
at key positions within the TM III, TM IV, and TM V, upregulate
the effects of MSP, suggesting that this molecule could prevent the
spontaneous receptor activation across the binding pocket extend
(Holst et al., 2006; Mokrosinski and Holst, 2010).
INTRACELLULAR PATHWAYS AND CONSTITUTIVE INTERNALIZATION
Inositol phosphate (IP) signaling pathway, through
Phospholipase C (PLC) activation, was the first specifically
associated with the GHS-R1a ligand-dependent activity (Adams
et al., 1995; Lei et al., 1995; Chen et al., 1996; Petersenn, 2002)
inducing intracellular calcium mobilization (Herrington and
Hille, 1994). Consequently, this pathway has been investigated
for determining the receptor constitutive signaling. PLC activa-
tion was demonstrated comparing heterologous HEK-293 and
COS-7 cells overexpressing the GHS-R1a to cells transfected
with the motilin receptor (that is the closest GPCR homolog of
GHS-R1a without constitutive activity; Holst et al., 2003). The
unusualy high GHS-R1a ligand-independent signaling level was
similar to that of the most famous highly constitutively active
GPCR, the virally encoded ORF74 receptor. To note, this paper
allowed characterizing MSP as a full GHS-R1a inverse agonist.
Indeed, this compound inhibits the GHS-R1a constitutive
ligand-independent IP accumulation and decreases the IP level to
that of cells transfected with the empty vector (Holst et al., 2003).
Lau et al. reported that GHS-R1a constitutive activity could
reduce apoptosis in HEK-293 overexpressing the (seabream)
sbGHS-R1a, through PKC-dependent caspase-3 inhibition (Lau
et al., 2009).
Gq/11-coupled GHS-R1a constitutive activity also resulted
in a dose-dependent but ligand-independent increase in the
CRE luciferase reporter while the full inverse agonist MSP
partially reversed this effect. To note, heterotrimeric Gq/11
protein-coupled receptors have previously been reported to phos-
phorylate the cAMP responsive element-binding protein (CREB)
by activating the CRE pathway as a result of calcium/calmoduline
kinase IV (CaMK IV) and/or protein kinase C (PKC) activation
(Matthews et al., 1994; Poulin et al., 2009) (Figure 1). Finally,
performing serum responsive element (SRE) reporter assay on
HEK-293 cells transfected with GHS-R1a revealed a 10-fold
increase in the ligand-independent signaling compared to the
cells transfected with the empty plasmid.
While many other signaling pathways have been shown to
play a role in the GHS-R1a ligand-dependent activation, the
GHS-R1a ligand-independent activation has not been investi-
gated. Indeed, Gi/o heterotrimeric pathway was clearly associated
with beta-arrestin-mediated ERK1/2 activation following GHS-
R1a activation by ghrelin (Camiña et al., 2007). Similarly, c-Src
that is involved in the GHS-R1a ghrelin-dependent Akt activa-
tion (via Gi/o-protein; Lodeiro et al., 2009) has not been studied
for the high basal level associated signaling pathways.
Since GHS-R1a exhibits an unusually high constitutive activ-
ity, it could be hypothesized that the downstream signaling
level could reflect the membrane expression level. In this con-
text, a better understanding of the mechanisms underlying and
modulating its plasma membrane expression was necessary. To
this end, GHS-R1a was tagged using M2 anti-FLAG antibody
labeling, thus allowing following the intracellular movement of
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FIGURE 1 | GHS-R1a constitutive activity leads to the dissociation of α
and βγ subunits of heterotrimeric G-proteins. The free Gq subunit
activates the PLC that cleaves PiP2 into IP3 and DAG. DAG activates the PKC,
which in turn actives the Ca2+ channels and inhibits the K+ channels
(continuous line). The effects of IP3 on the intracellular Ca2+ mobilization and
the origin of the Ca2+ that activates the Ca2+ calmodulin kinase (CaMK)
remain unclear and will need further investigations (dotted line). The binding
of the inverse agonist MSP to the GHS-R1a inhibits the G-protein signaling
and decreases the IP3 (via PLC) and CRE pathway (via phosphorylated CREB)
constitutive activation.
GHS-R1a. These experiments revealed a GHS-R1a constitutive
ligand-independent internalization and the receptor could be
trapped at the cell surface by the inverse agonist MSP. The punc-
tiform receptor intracellular labeling co-localizes with clathrin-
coated vesicles and recycling endosome markers (Holst et al.,
2003).
Unlike the GHS-R1a, GPR-39 receptor, a member of the ghre-
lin receptor family, is not constitutively internalized but it displays
a high ligand-independent signaling level (Holst et al., 2003).
Based on these observations, Holliday et al. developed an ele-
gant approach by switching the GHS-R1a C tail with that of the
GPR-39. The chimera, named GhR-39, was constitutively active
through the PLC pathway but its internalization was impaired.
Components supporting the constitutive activity could be neces-
sary but not sufficient for GHS-R1a endocytosis and additional
regulatory elements in the C-terminal domain may be involved
(Holliday et al., 2007).
GHS-R1a constitutive internalization requires the sequen-
tial activation of the monomeric G proteins Rab5 and Rab11.
Rab proteins control various important cellular processes, such
as endocytosis, trafficking, endosome fusion. and exocytosis
(Seachrist and Ferguson, 2003). These proteins regulate vesi-
cle transport and fusion with specific target compartments, the
early endosomes for Rab5, and the endosomal recycling compart-
ments such as the perinuclear recycling compartment (PNRC)
for Rab11. MSP-induced GHS-R1a membrane plasma anchor-
age is blocked by the constitutive expression of GTP-binding
mutants of Rabs (Rab5 Gln79Leu or Rab11 Gln70Leu) confirm-
ing that MSP naturally inhibits GHS-R1a internalization rather
than activates GHS-R1a neosynthesis and trafficking (Holliday
et al., 2007).
β-arrestin recruitment has been obviously investigated as it
appears as the most widely standard adaptor for GPCR endo-
cytosis (Lefkowitz, 1998) (Figure 2). Only ghrelin stimulation
induces GHSR-1a phosphorylation and β-arrestin 2 recruitment.
Besides, dominant-negative β-arrestin 2 construct, which com-
petes for clathrin interaction, does not inhibit the constitutive
endocytosis, supporting the hypothesis of a GHS-R1a β-arrestin-
independent constitutive internalization. These results suggest
that the aromatic residue VI:16, already mentioned above, could
act as “tethered biased agonist” rather than “tethered agonist”
because it blocks the receptor in a conformation that only induces
the Gq/11 protein activation without β-arrestin 2 recruitment
(Shukla et al., 2011; Reiter et al., 2012). To note, β-arrestin 2
recruitment has been reported to active the MAPK pathway. In
this context, the absence of β-arrestin 2 recruitment in basal
condition has been proposed to explain the absence of MAPK
pathway activation (Holliday et al., 2007).
Purified GHS-R1a monomers in a lipid disc showed that the
ghrelin receptor per se activates Gq/11 in the absence of agonist,
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FIGURE 2 | GHS-R1a activation by its endogenous ligand ghrelin leads to
the dissociation of α and βγ subunits of heterotrimeric G-proteins. The
βγ dimer recruits G-protein-receptor kinases (such as GRK2 or GRK3) to the
receptor, where they phosphorylate the agonist-bound receptor. These
phosphorylations lead to the recruitment of β-arrestins and activation of the
monomeric G-protein RAb5 that targets the receptor to early endosomes.
Then the receptor is addressed to the lysosome for degradation. GHS-R1a
constitutive activation recruits Rab5 without activation of the GRK, inducing
subsequent phosphorylation and β-arrestin recruitment. This constitutive
activation of Rab5 explains the receptor ligand-independent internalization
that is first addressed to the early endosome then to the PNRC (perinuclear
recycling compartment) where it activates the monomeric G-protein Rab11.
and that GHS-R1a constitutive activity is an intrinsic property
of the protein and is not influenced by its cellular environment
(Damian et al., 2012). In this context, the receptor isolated in lipid
discs recruits arrestin-2 in an agonist-dependent manner (Mary
et al., 2012), whereas it interacts with μ-AP2 (plasma membrane-
localized clathrin adaptor subunit) in the absence of ligand or in
the presence of ghrelin (Damian et al., 2012). Thus, μ-AP2 could
be involved in the basal regulation of GHS-R1a trafficking.
PHYSIOLOGICAL RELEVANCE
Many types of GPCR display a high ligand-independent signal-
ing in vitro (Seifert and Wenzel-Seifert, 2002). Among them,
GHS-R1a has been shown to display both the highest basal acti-
vation of Gq/11 (about 50% of its maximal activity) in vitro
(Holst et al., 2004), and substantial basal signaling for food
intake and weight control in vivo (Petersen et al., 2009; Els et al.,
2012). Pantel et al., who reported naturally occurring muta-
tions in the GHS-R1a sequence, have first shown a putative
link with physiological impairments in 2006. They reported a
substitutionmutation located within the first GHS-R1a exon, pre-
dicting the substitution of Alanine by Glutamate (Ala204Glu) in
two independent Moroccan families. This missense mutation is
located in the GHS-R1a ECL2 and affects a fully conserved amino
acid. HEK-293 cells stably transfected with WT and Ala204Glu-
mutant GHS-R1a showed, using POU1F1-luciferase reporter
assay that this mutation selectively abolishes the GHS-R1a ligand-
independent signaling without altering the Ghrelin-dependent
activity. Noteworthy, mutations altering exclusively the constitu-
tive activity are associated with familial short stature syndrome
and the latter can be partially reversed with GH treatment (Pantel
et al., 2006, 2009; Inoue et al., 2011). Wang reported another
uncharacterized GHS-R1a mutation affecting the Phe 279 residue
(Phe VI:16) recently identified as being of particular interest
for GHS-R1a constitutive activity. Noteworthy, the phenotype of
patients expressing this mutation is characterized by an increased
obesity and short stature (Wang, 2004). Regarding these different
but functionally similar mutations, Holst and Schwartz proposed
that the absence of GHS-R1a constitutively active signaling results
in a syndrome, characterized, not only by a short stature, but also
by obesity (Holst and Schwartz, 2006). This suggestion has been
confirmed recently using icv MSP administration that signifi-
cantly decreased the food intake, body weight, and neuropeptide
Y (NPY) and uncoupling protein 2 (UCP2) gene expression in the
hypothalamus (Petersen et al., 2009).
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Ligand-dependent GHS-R1a heterodimerizations have been
reported for the subtype 1 dopamine receptor that increases
dopamine signaling (Jiang et al., 2006), the somatostatin receptor-
5 that regulates insulin release (Park et al., 2012) and the
melanocortin-3 receptor that is involved in body weight regu-
lation and energy balance (Rediger et al., 2011, 2012). Also, the
dimerization of the GHS-R1a with the dopamine D2 receptor has
recently been shown to regulate appetite (Kern et al., 2012).
Its dimerization with the melanocortin-3 receptor, the D1
receptor, and the newly discovered 5-HT2C receptor may be
central in modulating and controlling GHS-R1a-mediated down-
stream signaling and subsequent satiety and appetite signaling,
as well as the rewarding and motivational aspects of food intake
(Schellekens et al., 2013). The understanding of the underlying
mechanisms leading to these activations may ultimately lead to
the development of new therapeutic strategies.
On the other hand, ghrelin and GHS-R1a knockout mice
explorations may allow the emergence of new regulatory prop-
erties of the ghrelin receptor constitutive activity. For exam-
ple, GHS-R1a constitutive activity increases limbic seizures in
rodents, the endogenous ligand being naturally anticonvulsive
(Portelli et al., 2012). In the mouse brain, deficits in spontaneous
receptor activity cause marked functional impairment in learning
and memory (Albarran-Zeckler et al., 2012). GHS-R1a signaling
is necessary for hippocampal-dependent learning and habituated
feeding responses (Davis et al., 2011). Ghrelin plays also a role
in sleep whereas the GHS-R1a will be more implicated in arousal
(Esposito et al., 2012).
To move beyond putative redundant compensation mech-
anisms, further in vivo investigations targetting the recep-
tor constitutive activity with appropriate pharmacological tools
(Mokrosinski and Holst, 2010; Sivertsen et al., 2011) would
be needed to determine the underlying physiological functions
linked to this constitutive activity.
CONCLUSION
Abundant evidence currently indicates that ghrelin, by its binding
to GHS-R1a, plays a role in various physiological functions that
led to the development of clinical trials to translate basic research
findings to human disease treatment and diagnosis (for review
Akamizu and Kangawa, 2012). Concerning the GHS-R1a consti-
tutive activity, most of the studies performed so far focused on
the molecular aspects. Even if some physiological relevance are
emerging for food intake regulation (see paragraph above), fur-
ther studies remain necessary to confirm the role played by the
GHS-R1a constitutive activity in the regulation of the GH axis.
Pituitary somatotroph adenomas express higher GHS-R1a tran-
script and protein levels than normal pituitary (Korbonits et al.,
1998; Barlier et al., 1999). Moreover, Pantel et al. (2006) have
shown that a reduced GHS-R1a constitutive activity impairs the
GH secretion. Thus, it should be interesting to test if the GHS-
R1a constitutive activity disrupts the GH hypersecretion observed
in acromegalic patients with somatotroph tumors (Acunzo et al.,
2008; Roche et al., 2012).
The signaling pathways associated with this high constitutive
activity should also be addressed. Knowing that the heterogene-
ity of the coupling on the signaling varies depending on the
tissue or cell type, it is crucial to address now these questions
in physiological or pathophysiological models. Depending on
the model, does the GHS-R1a ligand-independent CRE activa-
tion pass through the calcium/calmodulin kinase? And/or via the
cAMP/PKA pathways?
These issues are part of the many questions pending in this
field. Some of them may support the development of clini-
cal applications of GHS-R1a inverse agonists in physiological
disorders in the future, allowing developing novel and unique
therapies for various disorders, including intractable and seri-
ous diseases. Indeed, research on basic and clinical applications
of GHS-R1a inverse agonists will be challenging and potentially
rewarding.
ACKNOWLEDGMENTS
We thank very gratefully Prof. Isabelle Limon for helpful criti-
cisms and careful corrections of the manuscript. We acknowledge
Dr. Marie-Pierre Blanchard for her manuscript reading. This
work was supported by Aix-Marseille University and CNRS.
REFERENCES
Acunzo, J., Thirion, S., Roche, C.,
Saveanu, A., Gunz, G., Germanetti,
A. L., et al. (2008). Somatostatin
receptor sst2 decreases cell viabil-
ity and hormonal hypersecretion
and reverses octreotide resistance of
human pituitary adenomas. Cancer
Res. 68, 10163–10170.
Adams, E. F., Petersen, B., Lei, T.,
Buchfelder, M., and Fahlbusch,
R. (1995). The growth hormone
secretagogue, L-692, 429, induces
phosphatidylinositol hydroly-
sis and hormone secretion by
human pituitary tumors. Biochem.
Biophys. Res. Commun. 208,
555–561.
Akamizu, T., and Kangawa, K. (2012).
The physiological significance and
potential clinical applications of
ghrelin. Eur. J. Intern. Med. 23,
197–202.
Albarran-Zeckler, R. G., Brantley, A. F.,
and Smith, R. G. (2012). Growth
hormone secretagogue receptor
(GHS-R1a) knockout mice exhibit
improved spatial memory and
deficits in contextual memory.
Behav. Brain Res. 232, 13–19.
Arvanitakis, L., Geras-Raaka, E.,
and Gershengorn, M. C. (1998).
Constitutively signaling G-protein-
coupled receptors and human
disease. Trends Endocrinol. Metab.
9, 27–31.
Barlier, A., Zamora, A. J., Grino, M.,
Gunz, G., Pellegrini-Bouiller, I.,
Morange-Ramos, I., et al. (1999).
Expression of functional growth
hormone secretagogue receptors
in human pituitary adenomas:
polymerase chain reaction, triple
in-situ hybridization and cell cul-
ture studies. J. Neuroendocrinol. 11,
491–502.
Bowers, C. Y., Sartor, A. O., Reynolds,
G. A., and Badger, T. M. (1991). On
the actions of the growth hormone-
releasing hexapeptide, GHRP.
Endocrinology 128, 2027–2035.
Camiña, J. P., Lodeiro, M., Ischenko,
O., Martini, A. C., and Casanueva,
F. F. (2007). Stimulation by ghrelin
of p42/p44 mitogen-activated pro-
tein kinase through the GHS-R1a
receptor: role of G-proteins and
beta-arrestins. J. Cell. Physiol. 213,
187–200.
Castañeda, T. R., Tong, J., Datta, R.,
Culler, M., and Tschöp, M. H.
(2010). Ghrelin in the regulation
of body weight and metabolism.
Front. Neuroendocrinol. 31, 44–60.
doi: 10.1016/j.yfrne.2009.10.008
Chen, C., Wu, D., and Clarke, I.
J. (1996). Signal transduction sys-
tems employed by synthetic GH-
releasing peptides in somatotrophs.
J. Endocrinol. 148, 381–386.
Cheng, K., Chan, W. W., Barreto,
A., Convey, E. M., and Smith, R.
G. (1989). The synergistic effects
of His-D-Trp-Ala-Trp-D-Phe-
Lys-NH2 on growth hormone
(GH)-releasing factor-stimulated
GH release and intracellular
adenosine 3′, 5′-monophosphate
accumulation in rat primary pitu-
itary cell culture. Endocrinology 124,
2791–2798.
Cheng, K., Chan, W. W., Butler, B.,
Barreto, A., and Smith, R. G. (1991).
Evidence for a role of protein
www.frontiersin.org May 2013 | Volume 7 | Article 87 | 5
Mear et al. Ghrelin receptor and constitutive activity
kinase-C in His-D-Trp-Ala-Trp-D-
Phe-Lys-NH2-induced growth hor-
mone release from rat primary
pituitary cells. Endocrinology 129,
3337–3342.
Cruz, C. R. Y., and Smith, R. G. (2008).
The growth hormone secretagogue
receptor. Vitam. Horm. 77, 47–88.
Damian, M., Marie, J., Leyris, J. P.,
Fehrentz, J. A., Verdié, P., Martinez,
J., et al. (2012). High constitutive
activity is an intrinsic feature of
ghrelin receptor protein: a study
with a functional monomeric GHS-
R1a receptor reconstituted in lipid
discs. J. Biol. Chem. 287, 3630–3641.
Davis, J. F., Choi, D. L., Clegg, D. J.,
and Benoit, S. C. (2011). Signaling
through the ghrelin receptor mod-
ulates hippocampal function and
meal anticipation in mice. Physiol.
Behav. 103, 39–43.
Elling, C. E., Thirstrup, K., Holst,
B., and Schwartz, T. W. (1999).
Conversion of agonist site to
metal-ion chelator site in the
beta(2)-adrenergic receptor.
Proc. Natl. Acad. Sci. U.S.A. 96,
12322–12327.
Els, S., Schild, E., Petersen, P. S., Kilian,
T. M., Mokrosinski, J., Frimurer, T.
M., et al. (2012). An aromatic region
to induce a switch between ago-
nism and inverse agonism at the
ghrelin receptor. J. Med. Chem. 55,
7437–7449.
Esposito, M., Pellinen, J., Kapás, L.,
and Szentirmai, É. (2012). Impaired
wake-promoting mechanisms in
ghrelin receptor-deficient mice. Eur.
J. Neurosci. 35, 233–243.
Floquet, N., M’Kadmi, C., Perahia, D.,
Gagne, D., Bergé, G., Marie, J., et al.
(2010). Activation of the ghrelin
receptor is described by a privileged
collective motion: a model for con-
stitutive and agonist-induced acti-
vation of a sub-class A G-protein
coupled receptor (GPCR). J. Mol.
Biol. 395, 769–784.
Gozé, C., Bergé, G., M’Kadmi, C.,
Floquet, N., Gagne, D., Galleyrand,
J. C., et al. (2010). Involvement of
tryptophan W276 and of two sur-
rounding amino acid residues in
the high constitutive activity of the
ghrelin receptor GHS-R1a. Eur. J.
Pharmacol. 643, 153–161.
Herrington, J., and Hille, B. (1994).
Growth hormone-releasing
hexapeptide elevates intracellu-
lar calcium in rat somatotropes by
two mechanisms. Endocrinology
135, 1100–1108.
Holliday, N. D., Holst, B., Rodionova,
E. A., Schwartz, T. W., and Cox,
H. M. (2007). Importance of
constitutive activity and arrestin-
independent mechanisms for
intracellular trafficking of the ghre-
lin receptor. Mol. Endocrinol. 21,
3100–3112.
Holst, B., Cygankiewicz, A., Jensen, T.
H., Ankersen, M., and Schwartz,
T. W. (2003). High constitutive
signaling of the ghrelin receptor–
identification of a potent inverse
agonist. Mol. Endocrinol. 17,
2201–2210.
Holst, B., Holliday, N. D., Bach, A.,
Elling, C. E., Cox, H. M., and
Schwartz, T. W. (2004). Common
structural basis for constitutive
activity of the ghrelin recep-
tor family. J. Biol. Chem. 279,
53806–53817.
Holst, B., Lang, M., Brandt, E., Bach,
A., Howard, A., Frimurer, T. M.,
et al. (2006). Ghrelin receptor
inverse agonists: identification of an
active peptide core and its interac-
tion epitopes on the receptor. Mol.
Pharmacol. 70, 936–946.
Holst, B., Mokrosinski, J., Lang, M.,
Brandt, E., Nygaard, R., Frimurer,
T. M., et al. (2007). Identification
of an efficacy switch region in
the ghrelin receptor responsible for
interchange between agonism and
inverse agonism. J. Biol. Chem. 282,
15799–15811.
Holst, B., and Schwartz, T. W. (2006).
Ghrelin receptor mutations—too
little height and too much hunger.
J. Clin. Invest. 116, 637–641.
Howard, A. D., Feighner, S. D., Cully,
D. F., Arena, J. P., Liberator, P. A.,
Rosenblum, C. I., et al. (1996). A
receptor in pituitary and hypothala-
mus that functions in growth hor-
mone release. Science 273, 974–977.
Inoue, H., Kangawa, N., Kinouchi,
A., Sakamoto, Y., Kimura, C.,
Horikawa, R., et al. (2011).
Identification and functional
analysis of novel human growth
hormone secretagogue receptor
(GHSR) gene mutations in Japanese
subjects with short stature. J. Clin.
Endocrinol. Metab. 96, E373–E378.
Jiang, H., Betancourt, L., and Smith,
R. G. (2006). Ghrelin amplifies
dopamine signaling by cross talk
involving formation of growth
hormone secretagogue recep-
tor/dopamine receptor subtype 1
heterodimers. Mol. Endocrinol. 20,
1772–1785.
Kern, A., Albarran-Zeckler, R., Walsh,
H. E., and Smith, R. G. (2012). Apo-
ghrelin receptor forms heteromers
with DRD2 in hypothalamic neu-
rons and is essential for anorex-
igenic effects of DRD2 agonism.
Neuron 73, 317–332.
Kojima, M., Hosoda, H., Date, Y.,
Nakazato, M., Matsuo, H., and
Kangawa, K. (1999). Ghrelin is a
growth-hormone-releasing acylated
peptide from stomach. Nature 402,
656–660.
Kojima, M., Hosoda, H., Matsuo, H.,
and Kangawa, K. (2001). Ghrelin:
discovery of the natural endoge-
nous ligand for the growth hor-
mone secretagogue receptor. Trends
Endocrinol. Metab. 12, 118–122.
Korbonits, M., Jacobs, R. A., Aylwin,
S. J., Burrin, J. M., Dahia, P.
L., Monson, J. P., et al. (1998).
Expression of the growth hor-
mone secretagogue receptor in pitu-
itary adenomas and other neuroen-
docrine tumors. J. Clin. Endocrinol.
Metab. 83, 3624–3630.
Lau, P. N., Chow, K. B. S., Chan, C.
B., Cheng, C. H. K., and Wise,
H. (2009). The constitutive activ-
ity of the ghrelin receptor attenu-
ates apoptosis via a protein kinase
C-dependent pathway. Mol. Cell.
Endocrinol. 299, 232–239.
Lefkowitz, R. J. (1998). G Protein-
coupled Receptors. J. Biol. Chem.
273, 18677–18680.
Lei, T., Buchfelder, M., Fahlbusch, R.,
and Adams, E. F. (1995). Growth
hormone releasing peptide (GHRP-
6) stimulates phosphatidylinositol
(PI) turnover in human pitu-
itary somatotroph cells. J. Mol.
Endocrinol. 14, 135–138.
Lodeiro, M., Theodoropoulou, M.,
Pardo, M., Casanueva, F. F., and
Camiña, J. P. (2009). c-Src regu-
lates Akt signaling in response to
ghrelin via beta-arrestin signaling-
independent and -dependent mech-
anisms. PLoS ONE 4:e4686. doi:
10.1371/journal.pone.0004686
Mary, S., Damian, M., Louet, M.,
Floquet, N., Fehrentz, J., Marie, J.,
et al. (2012). Ligands and signaling
proteins govern the conformational
landscape explored by a G protein-
coupled receptor. Proc. Natl. Acad.
Sci. U.S.A. 109, 8304–8309.
Matthews, R. P., Guthrie, C. R.,
Wailes, L. M., Zhao, X., Means,
A. R., and McKnight, G. S.
(1994). Calcium/calmodulin-
dependent protein kinase types
II and IV differentially regulate
CREB-dependent gene expression.
Mol. Cell. Biol. 14, 6107–6116.
Mokrosinski, J., Frimurer, T. M.,
Sivertsen, B., Schwartz, T. W., and
Holst, B. (2012). Modulation of
constitutive activity and signaling
bias of the ghrelin receptor by
conformational constraint in the
second extracellular loop. J. Biol.
Chem. 287, 33488–33502.
Mokrosinski, J., and Holst, B. (2010).
Modulation of the constitutive
activity of the ghrelin receptor by
use of pharmacological tools and
mutagenesis. Methods Enzymol. 484,
53–73.
Pantel, J., Legendre, M., Cabrol, S.,
Hilal, L., Hajaji, Y., Nivot, S., et al.
(2006). Loss of constitutive activ-
ity of the growth hormone secre-
tagogue receptor in familial short
stature. J. Clin. Invest. 116, 760–768.
Pantel, J., Legendre, M., Nivot, S.,
Morisset, S., Vie-Luton, M. P., Le
Bouc, Y., et al. (2009). Recessive
isolated growth hormone deficiency
and mutations in the ghrelin recep-
tor. J. Clin. Endocrinol. Metab. 94,
4334–4341.
Park, S., Jiang, H., Zhang, H., and
Smith, R. G. (2012). Modification
of ghrelin receptor signaling by
somatostatin receptor-5 regulates
insulin release. Proc. Natl. Acad. Sci.
U.S.A. 109, 19003–19008.
Petersen, P. S., Woldbye, D. P. D.,
Madsen, A. N., Egerod, K. L., Jin,
C., Lang, M., et al. (2009). In vivo
characterization of high Basal sig-
naling from the ghrelin receptor.
Endocrinology 150, 4920–4930.
Petersenn, S. (2002). Structure and
regulation of the growth hormone
secretagogue receptor. Minerva
Endocrinol. 27, 243–256.
Pong, S. S., Chaung, L. Y., Dean, D. C.,
Nargund, R. P., Patchett, A. A., and
Smith, R. G. (1996). Identification
of a new G-protein-linked receptor
for growth hormone secretagogues.
Mol. Endocrinol. 10, 57–61.
Portelli, J., Thielemans, L., Ver Donck,
L., Loyens, E., Coppens, J., Aourz,
N., et al. (2012). Inactivation of the
constitutively active ghrelin recep-
tor attenuates limbic seizure activ-
ity in rodents. Neurotherapeutics 9,
658–672.
Poulin, B., Maccario, H., Thirion, S.,
Junoy, B., Boyer, B., Enjalbert, A.,
et al. (2009). Ubiquitination as a
priming process of PKC alpha and
PKC epsilon degradation in the
alphaT3-1 gonadotrope cell line.
Neuroendocrinology 89, 252–266.
Rediger, A., Piechowski, C. L.,
Habegger, K., Grüters, A., Krude,
H., Tschöp, M. H., et al. (2012).
MC4R dimerization in the paraven-
tricular nucleus and GHSR/MC3R
heterodimerization in the arcu-
ate nucleus: is there relevance
for body weight regulation?
Neuroendocrinology 95, 277–288.
Rediger, A., Piechowski, C. L., Yi, C. X.,
Tarnow, P., Strotmann, R., Grüters,
A., et al. (2011). Mutually oppo-
site signal modulation by hypotha-
lamic heterodimerization of ghre-
lin and melanocortin-3 receptors.
J. Biol. Chem. 286, 39623–39631.
Reiter, E., Ahn, S., Shukla, A. K., and
Lefkowitz, R. J. (2012). Molecular
Frontiers in Neuroscience | Neuroendocrine Science May 2013 | Volume 7 | Article 87 | 6
Mear et al. Ghrelin receptor and constitutive activity
mechanism of β-arrestin-biased
agonism at seven-transmembrane
receptors. Annu. Rev. Pharmacol.
Toxicol. 52, 179–197.
Roche, C., Rasolonjanahary, R.,
Thirion, S., Goddard, I., Fusco, A.,
Figarella-Branger, D., et al. (2012).
Inactivation of transcription factor
pit-1 to target tumoral somatolac-
totroph cells. Hum. Gene Ther. 23,
104–114.
Schellekens, H., Van Oeffelen, W.
E., Dinan, T. G., and Cryan, J.
F. (2013). Promiscuous dimer-
ization of the growth hormone
secretagogue receptor (GHS-
R1a) attenuates ghrelin-mediated
signaling. J. Biol. Chem. 288,
181–191.
Schwartz, T. W., Frimurer, T. M., Holst,
B., Rosenkilde, M. M., and Elling,
C. E. (2006). Molecular mechanism
of 7TM receptor activation–a global
toggle switch model. Annu. Rev.
Pharmacol. Toxicol. 46, 481–519.
Seachrist, J. L., and Ferguson, S.
S. (2003). Regulation of G
protein-coupled receptor endo-
cytosis and trafficking by Rab
GTPases. Life Sci. 74, 225–235.
Seifert, R., and Wenzel-Seifert, K.
(2002). Constitutive activity of
G-protein-coupled receptors: cause
of disease and common prop-
erty of wild-type receptors. Arch.
Pharmacol. 366, 381–416.
Shukla, A. K., Xiao, K., and Lefkowitz,
R. J. (2011). Emerging paradigms
of β-arrestin-dependent seven
transmembrane receptor sig-
naling. Trends Biochem. Sci. 36,
457–469.
Sivertsen, B., Lang, M., Frimurer, T.
M., Holliday, N. D., Bach, A., Els,
S., et al. (2011). Unique interaction
pattern for a functionally biased
ghrelin receptor agonist. J. Biol.
Chem. 286, 20845–20860.
Smit, M. J., Vischer, H. F., Bakker, R.
A., Jongejan, A., Timmerman,
H., Pardo, L., et al. (2007).
Pharmacogenomic and struc-
tural analysis of constitutive g
protein-coupled receptor activity.
Annu. Rev. Pharmacol. Toxicol. 47,
53–87.
Stengel, A., and Taché, Y. (2012).
Ghrelin—a pleiotropic hormone
secreted from endocrine x/a-like
cells of the stomach. Front. Neurosci.
6:24. doi: 10.3389/fnins.2012.
00024
Valentin-Hansen, L., Holst, B.,
Frimurer, T. M., and Schwartz,
T. W. (2012). PheVI:09 (Phe6.44)
as a sliding microswitch in
seven-transmembrane (7TM) G
protein-coupled receptor activation.
J. Biol. Chem. 287, 43516–43526.
Wang, H. J. (2004). Ghrelin recep-
tor gene: identification of several
sequence variants in extremely
obese children and adoles-
cents, healthy normal-weight
and underweight students, and
children with short normal stature.
J. Clin. Endocrinol. Metab. 89,
157–162.
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 31 December 2012; accepted:
09 May 2013; published online: 29 May
2013.
Citation: Mear Y, Enjalbert A and
Thirion S (2013) GHS-R1a constitutive
activity and its physiological relevance.
Front. Neurosci. 7:87. doi: 10.3389/fnins.
2013.00087
This article was submitted to Frontiers
in Neuroendocrine Science, a specialty of
Frontiers in Neuroscience.
Copyright © 2013 Mear, Enjalbert
and Thirion. This is an open-access
article distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are
credited and subject to any copyright
notices concerning any third-party
graphics etc.
www.frontiersin.org May 2013 | Volume 7 | Article 87 | 7
